{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:51:04Z","timestamp":1792450264506,"version":"4.5.0"},"reference-count":163,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001960","name":"American Society for Radiation Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001960","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.prro.2026.07.002","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T12:19:08Z","timestamp":1786450748000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline"],"prefix":"10.1016","author":[{"given":"Michael D.","family":"Chuong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan R.","family":"Jethwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan","family":"Ludmir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amol","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marsha","family":"Reyngold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramila Rani","family":"Anne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin L.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Frakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyn","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsay","family":"Romak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina N.","family":"Sanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachna","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie S.K.","family":"Takayesu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego Santos","family":"Toesca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2703-0501","authenticated-orcid":false,"given":"Lisa","family":"Bradfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2026.07.002_bib0001","series-title":"Clinical Practice Guidelines We Can Trust","year":"2011"},{"key":"10.1016\/j.prro.2026.07.002_bib0002","series-title":"Finding What Works in Health Care: Standards for Systematic Reviews","year":"2011"},{"key":"10.1016\/j.prro.2026.07.002_bib0003","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.prro.2026.07.002_bib0004","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.prro.2026.07.002_bib0005","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","article-title":"Pancreatic cancer: A review","volume":"326","author":"Park","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2026.07.002_bib0006","doi-asserted-by":"crossref","first-page":"dju011","DOI":"10.1093\/jnci\/dju011","article-title":"Pancreatic adenocarcinoma: Treating a systemic disease with systemic therapy","volume":"106","author":"Sohal","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.prro.2026.07.002_bib0007","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.07.002_bib0008","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.07.002_bib0009","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1016\/S0140-6736(23)01366-1","article-title":"NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): A randomised, open-label, phase 3 trial","volume":"402","author":"Wainberg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2026.07.002_bib0010","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.prro.2019.06.016","article-title":"Radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline","volume":"9","author":"Palta","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0011","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO-24-01502","article-title":"Benefit of chemoradiotherapy versus chemotherapy after induction therapy for conversion of unresectable into resectable pancreatic cancer: The randomized CONKO-007 trial","volume":"43","author":"Fietkau","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0012","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: The A021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0013","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0014","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1016\/S1470-2045(25)00363-8","article-title":"Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): A multicentre, open-label, phase 3 randomised trial","volume":"26","author":"Janssen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0015","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1200\/JCO-25-02520","article-title":"Adjuvant chemotherapy \u00b1 chemoradiotherapy for adenocarcinoma of the pancreatic head: Results of the radiotherapy random assignment of NRG oncology\/RTOG 0848","volume":"44","author":"Abrams","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0016","article-title":"Patterns of failure after definitive ablative 5-fraction stereotactic body radiation therapy for inoperable pancreatic ductal adenocarcinoma","author":"Chuong","year":"2026","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0017","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2021.0057","article-title":"Association of ablative radiation therapy with survival among patients with inoperable pancreatic cancer","volume":"7","author":"Reyngold","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0018","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.semradonc.2025.08.003","article-title":"Optimal target volume delineation for pancreatic cancer: Triangulating what should be targeted","volume":"35","author":"Narang","year":"2025","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0019","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/S1470-2045(24)00223-7","article-title":"Celiac plexus radiosurgery for pain management in advanced cancer: A multicentre, single-arm, phase 2 trial","volume":"25","author":"Lawrence","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0020","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ijrobp.2023.08.055","article-title":"Impact of short-course palliative radiation therapy on pancreatic cancer-related pain: Prospective phase 2 nonrandomized PAINPANC trial","volume":"118","author":"Tello Valverde","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0021","doi-asserted-by":"crossref","first-page":"3795","DOI":"10.1200\/JCO.24.00081","article-title":"Addition of metastasis-directed therapy to systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): A multicenter, randomized phase II trial","volume":"42","author":"Ludmir","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0022","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): A four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2026.07.002_bib0023","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/SLA.0000000000002705","article-title":"Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: A prospective, randomized, open-label, multicenter phase 2\/3 trial","volume":"268","author":"Jang","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0024","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1245\/s10434-018-6931-6","article-title":"How does chemoradiotherapy following induction FOLFIRINOX improve the results in resected borderline or locally advanced pancreatic adenocarcinoma? An AGEO-FRENCH multicentric cohort","volume":"26","author":"Pietrasz","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.gassur.2026.102358","article-title":"Neoadjuvant stereotactic body vs conventionally fractionated radiation therapy for borderline resectable and locally advanced pancreatic cancer: A propensity score-matched analysis","volume":"30","author":"Shimizu","year":"2026","journal-title":"J Gastrointest Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0026","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total neoadjuvant therapy with FOLFIRINOX in combination with losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase 2 clinical trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110064","article-title":"Stereotactic MR-guided on-table adaptive radiation therapy (SMART) for borderline resectable and locally advanced pancreatic cancer: A multi-center, open-label phase 2 study","volume":"191","author":"Chuong","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0028","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.prro.2022.02.009","article-title":"Multiagent chemotherapy and stereotactic body radiation therapy in patients with unresectable pancreatic adenocarcinoma: A prospective nonrandomized controlled trial","volume":"12","author":"Hill","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0029","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.ijrobp.2023.05.023","article-title":"A multi-institutional phase 2 trial of ablative 5-fraction stereotactic magnetic resonance-guided on-table adaptive radiation therapy for borderline resectable and locally advanced pancreatic cancer","volume":"117","author":"Parikh","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.radonc.2020.11.006","article-title":"A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome","volume":"155","author":"Teriaca","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0031","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: The LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2026.07.002_bib0032","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cncr.29161","article-title":"Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma","volume":"121","author":"Herman","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.prro.2026.07.002_bib0033","article-title":"Surgical and pathologic outcomes of pancreatic adenocarcinoma (PA) after preoperative ablative stereotactic magnetic resonance image guided adaptive radiation therapy (A-SMART)","volume":"7","author":"Bryant","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0034","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MPA.0000000000002011","article-title":"Efficacy and safety of neoadjuvant chemoradiation therapy administered for 5 versus 2 weeks for resectable and borderline resectable pancreatic cancer","volume":"51","author":"Suto","year":"2022","journal-title":"Pancreas"},{"key":"10.1016\/j.prro.2026.07.002_bib0035","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.ijrobp.2015.08.026","article-title":"Health-related quality of life in SCALOP, a randomized phase 2 trial comparing chemoradiation therapy regimens in locally advanced pancreatic cancer","volume":"93","author":"Hurt","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0036","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1470-2045(13)70021-4","article-title":"Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial","volume":"14","author":"Mukherjee","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0037","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.ijrobp.2015.12.003","article-title":"Focal radiation therapy dose escalation improves overall survival in locally advanced pancreatic cancer patients receiving induction chemotherapy and consolidative chemoradiation","volume":"94","author":"Krishnan","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0038","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1245\/s10434-011-1630-6","article-title":"Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup\/RTOG 9704 phase III trial","volume":"18","author":"Regine","year":"2011","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0039","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Pancreatic adenocarcinoma. Accessed May 18, 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/pancreatic.pdf"},{"key":"10.1016\/j.prro.2026.07.002_bib0040","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S2468-1253(23)00405-3","article-title":"Neoadjuvant FOLFIRINOX versus upfront surgery for resectable pancreatic head cancer (NORPACT-1): A multicentre, randomised, phase 2 trial","volume":"9","author":"Labori","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2026.07.002_bib0041","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/SLA.0000000000006730","article-title":"Neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer: Results of the randomized phase II\/III prep-02\/JSAP05 trial","volume":"283","author":"Unno","year":"2026","journal-title":"Ann Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0042","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2022.3829","article-title":"Five-Year Outcomes of FOLFIRINOX vs gemcitabine as adjuvant therapy for pancreatic cancer: A randomized clinical trial","volume":"8","author":"Conroy","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0043","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1200\/JCO.22.01134","article-title":"Adjuvant nab-paclitaxel\u202f+\u202fgemcitabine in resected pancreatic ductal adenocarcinoma: Results from a randomized, open-label, phase III trial","volume":"41","author":"Tempero","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0044","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1001\/jamasurg.2019.3337","article-title":"Patterns of recurrence after resection of pancreatic ductal adenocarcinoma: A secondary analysis of the ESPAC-4 randomized adjuvant chemotherapy trial","volume":"154","author":"Jones","year":"2019","journal-title":"JAMA Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0045","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.pan.2024.07.017","article-title":"Recurrence pattern and its risk factors in patients with resected pancreatic ductal adenocarcinoma - A retrospective analysis of 272 patients","volume":"24","author":"Brunner","year":"2024","journal-title":"Pancreatology"},{"key":"10.1016\/j.prro.2026.07.002_bib0046","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/SLA.0b013e31823d813c","article-title":"Perineural invasion and lymph node involvement as indicators of surgical outcome and pattern of recurrence in the setting of preoperative gemcitabine-based chemoradiation therapy for resectable pancreatic cancer","volume":"255","author":"Takahashi","year":"2012","journal-title":"Ann Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0047","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1245\/s10434-009-0743-7","article-title":"Adjuvant chemoradiation for pancreatic adenocarcinoma: The Johns Hopkins Hospital-Mayo Clinic collaborative study","volume":"17","author":"Hsu","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0048","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.ijrobp.2014.07.024","article-title":"Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer","volume":"90","author":"Morganti","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0049","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/j.ejso.2020.07.029","article-title":"Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma","volume":"46","author":"Kim","year":"2020","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0050","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"8","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"key":"10.1016\/j.prro.2026.07.002_bib0051","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1245\/ASO.2006.08.011","article-title":"Borderline resectable pancreatic cancer: Definitions, management, and role of preoperative therapy","volume":"13","author":"Varadhachary","year":"2006","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0052","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1245\/s10434-009-0408-6","article-title":"Pretreatment assessment of resectable and borderline resectable pancreatic cancer: Expert consensus statement","volume":"16","author":"Callery","year":"2009","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0053","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.surg.2021.12.013","article-title":"Radiation therapy in borderline resectable pancreatic cancer: A review","volume":"172","author":"Turner","year":"2022","journal-title":"Surgery"},{"key":"10.1016\/j.prro.2026.07.002_bib0054","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1200\/JCO.2008.17.7188","article-title":"DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer","volume":"27","author":"Iacobuzio-Donahue","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0055","doi-asserted-by":"crossref","first-page":"711","DOI":"10.6004\/jnccn.2018.7013","article-title":"Clinical impact of local progression in pancreatic cancer","volume":"16","author":"Cardillo","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.prro.2026.07.002_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100552","article-title":"Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: Results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113)","volume":"7","author":"Hartlapp","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.prro.2026.07.002_bib0057","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1245\/s10434-025-17199-8","article-title":"Outcomes in locally advanced pancreatic cancer after induction ablative radiation therapy and resection","volume":"32","author":"Blair","year":"2025","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0058","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jviscsurg.2015.11.014","article-title":"Modified Appleby procedure for borderline resectable\/locally advanced distal pancreatic adenocarcinoma: A major procedure for selected patients","volume":"153","author":"Cesaretti","year":"2016","journal-title":"J Visc Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0059","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hpb.2017.02.437","article-title":"Superior mesenteric artery (SMA) resection during pancreatectomy for malignant disease of the pancreas: A systematic review","volume":"19","author":"Jegatheeswaran","year":"2017","journal-title":"HPB (Oxford)"},{"key":"10.1016\/j.prro.2026.07.002_bib0060","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1016\/j.surg.2015.04.031","article-title":"Underuse of surgical resection among elderly patients with early-stage pancreatic cancer","volume":"158","author":"He","year":"2015","journal-title":"Surgery"},{"key":"10.1016\/j.prro.2026.07.002_bib0061","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1089\/pancan.2020.0011","article-title":"Factors associated with treatment and survival of early stage pancreatic cancer in the era of modern chemotherapy: An analysis of the National Cancer Database","volume":"6","author":"Watson","year":"2020","journal-title":"J Pancreat Cancer"},{"key":"10.1016\/j.prro.2026.07.002_bib0062","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jgo.2019.12.006","article-title":"Patterns of care and treatment outcomes in patients age 80 or older with non-metastatic pancreatic cancer","volume":"11","author":"Li","year":"2020","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0063","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.3390\/cancers15082213","article-title":"Survival outcomes and failure patterns in patients with inoperable non-metastatic pancreatic cancer treated with definitive radiotherapy","volume":"15","author":"Cao","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.prro.2026.07.002_bib0064","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jamaoncol.2025.0460","article-title":"Nonoperative management of technically resectable pancreatic cancer with ablative radiation therapy","volume":"11","author":"Reyngold","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jss.2019.07.024","article-title":"Implications of prolonged time to pancreaticoduodenectomy after neoadjuvant chemoradiation","volume":"245","author":"Teng","year":"2020","journal-title":"J Surg Res"},{"key":"10.1016\/j.prro.2026.07.002_bib0066","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ijrobp.2022.07.015","article-title":"MR-guided radiation therapy with concurrent gemcitabine\/nab-paclitaxel chemotherapy in inoperable pancreatic cancer: A TITE-CRM phase I trial","volume":"115","author":"Kim","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0067","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2014.06.066","article-title":"Single- versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: Outcomes and toxicity","volume":"90","author":"Pollom","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0068","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: A phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0069","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1002\/cam4.4527","article-title":"High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy","volume":"11","author":"Hill","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.07.002_bib0070","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ijrobp.2021.07.1698","article-title":"Pancreatic stereotactic body radiation therapy with or without hypofractionated elective nodal irradiation","volume":"112","author":"Miller","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0071","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.888462","article-title":"Induction chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy for inoperable pancreas cancer","volume":"12","author":"Chuong","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0072","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3109\/02841861003660056","article-title":"Capecitabine based postoperative accelerated chemoradiation of pancreatic carcinoma. A dose-escalation study","volume":"49","author":"Morganti","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0073","doi-asserted-by":"crossref","DOI":"10.1001\/jamasurg.2016.1137","article-title":"Preoperative modified FOLFIRINOX treatment followed by capecitabine-based chemoradiation for borderline resectable pancreatic cancer: Alliance for clinical trials in oncology trial A021101","volume":"151","author":"Katz","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0074","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0075","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/j.ijrobp.2025.06.1203","article-title":"Maximal ablative irradiation because of encasement for patients with potentially resectable locally advanced pancreatic cancer: Final results of the phase II MAIBE trial","volume":"123","author":"Reyngold","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0076","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1016\/j.ijrobp.2012.02.051","article-title":"A phase I\/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer","volume":"84","author":"Ben-Josef","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0077","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1177\/1533034616650778","article-title":"Can Stereotactic body radiation therapy be a viable and efficient therapeutic option for unresectable locally advanced pancreatic adenocarcinoma? Results of a phase 2 study","volume":"16","author":"Comito","year":"2017","journal-title":"Technol Cancer Res Treat"},{"key":"10.1016\/j.prro.2026.07.002_bib0078","article-title":"CT-guided online adaptive stereotactic body radiotherapy for pancreas ductal adenocarcinoma: Dosimetric and initial clinical experience","volume":"48","author":"Lee","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0079","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.3390\/cancers17152596","article-title":"Multi-institutional comparison of ablative 5-fraction magnetic resonance-guided online adaptive versus 15\/25-fraction computed tomography-guided moderately hypofractionated offline adapted radiation therapy for locally advanced pancreatic cancer","volume":"17","author":"Chuong","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.prro.2026.07.002_bib0080","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1016\/j.prro.2024.07.001","article-title":"Patterns of locoregional pancreatic cancer recurrence after total neoadjuvant therapy and implications on optimal neoadjuvant radiation treatment volumes","volume":"15","author":"Beltran Ponce","year":"2025","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0081","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.ijrobp.2013.09.005","article-title":"Mapping patterns of local recurrence after pancreaticoduodenectomy for pancreatic adenocarcinoma: A new approach to adjuvant radiation field design","volume":"87","author":"Dholakia","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0082","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000518","article-title":"Pattern of marginal local failure in a phase II trial of neoadjuvant chemotherapy and stereotactic body radiation therapy for resectable and borderline resectable pancreas cancer","volume":"42","author":"Kharofa","year":"2019","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0083","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/jmri.21210","article-title":"Pancreatic cancer: Correlation of MR findings, clinical features, and tumor grade","volume":"26","author":"Elias","year":"2007","journal-title":"J Magn Reson Imaging"},{"key":"10.1016\/j.prro.2026.07.002_bib0084","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2019.01.075","article-title":"Patterns of local failure after stereotactic body radiation therapy and sequential chemotherapy as initial treatment for pancreatic cancer: Implications of target volume design","volume":"104","author":"Zhu","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0085","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.ijrobp.2024.10.026","article-title":"NRG oncology international consensus contouring atlas on target volumes and dosing strategies for dose-escalated pancreatic cancer radiation therapy","volume":"121","author":"Sanford","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0086","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.prro.2022.01.005","article-title":"Location, location, location: What should be targeted beyond gross disease for localized pancreatic ductal adenocarcinoma? Proposal of a standardized clinical tumor volume for pancreatic ductal adenocarcinoma of the head: The \"triangle volume\"","volume":"12","author":"Hill","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0087","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ijrobp.2023.06.230","article-title":"Utilization of the triangle volume in patients with localized PDAC undergoing pre-operative SBRT: Report of early outcomes","volume":"117","author":"Mao","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0088","first-page":"7023","article-title":"A prospective study of intensity-modified radiation therapy in comparison with conventional 3D-RT for BR pancreatic cancer patients with arterial involvement","volume":"37","author":"Masui","year":"2017","journal-title":"Anticancer Res"},{"key":"10.1016\/j.prro.2026.07.002_bib0089","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.prro.2015.09.006","article-title":"Intensity modulated radiation therapy reduces gastrointestinal toxicity in locally advanced pancreas cancer","volume":"6","author":"Prasad","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0090","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.3747\/co.23.2771","article-title":"Dosimetric and clinical toxicity comparison of critical organ preservation with three-dimensional conformal radiotherapy, intensity-modulated radiotherapy, and RapidArc for the treatment of locally advanced cancer of the pancreatic head","volume":"23","author":"Jin","year":"2016","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0091","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.ijrobp.2017.03.042","article-title":"Inter- and intrafractional variation in the 3-dimensional positions of pancreatic tumors due to respiration under real-time monitoring","volume":"98","author":"Akimoto","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0092","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.radonc.2012.02.012","article-title":"Quantifying motion for pancreatic radiotherapy margin calculation","volume":"103","author":"Whitfield","year":"2012","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110347","article-title":"Adaptive MRI-guided stereotactic body radiation therapy for locally advanced pancreatic cancer - A phase II study","volume":"197","author":"Weisz Ejlsmark","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0094","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijrobp.2013.02.022","article-title":"Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated","volume":"86","author":"Chuong","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0095","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5009\/gnl15186","article-title":"A comparison of gastrointestinal toxicities between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for pancreatic cancer","volume":"10","author":"Lee","year":"2016","journal-title":"Gut Liver"},{"key":"10.1016\/j.prro.2026.07.002_bib0096","doi-asserted-by":"crossref","first-page":"e615","DOI":"10.1016\/j.ijrobp.2011.04.045","article-title":"Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer","volume":"81","author":"Mahadevan","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0097","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.3390\/cancers14235730","article-title":"Isotoxic high-dose stereotactic body radiotherapy (iHD-SBRT) versus conventional chemoradiotherapy for localized pancreatic cancer: A single cancer center evaluation","volume":"14","author":"Manderlier","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.prro.2026.07.002_bib0098","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijrobp.2010.02.030","article-title":"Phase II trial of full-dose gemcitabine and bevacizumab in combination with attenuated three-dimensional conformal radiotherapy in patients with localized pancreatic cancer","volume":"80","author":"Small","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0099","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ijrobp.2011.08.026","article-title":"Analysis of local control in patients receiving IMRT for resected pancreatic cancers","volume":"83","author":"Yovino","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0100","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/1754-9485.12294","article-title":"Use of implanted gold fiducial markers with MV-CBCT image-guided IMRT for pancreatic tumours","volume":"59","author":"Packard","year":"2015","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0101","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ijrobp.2018.08.021","article-title":"The clinical and dosimetric impact of real-time target tracking in pancreatic SBRT","volume":"103","author":"Vinogradskiy","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0102","article-title":"Proton therapy for unresectable and medically inoperable locally advanced pancreatic cancer: Results from a multi-institutional prospective registry","volume":"8","author":"Eckstein","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0103","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.3390\/curroncol30070513","article-title":"Can STEreotactic Body Radiation Therapy (SBRT) improve the prognosis of unresectable locally advanced pancreatic cancer? Long-term clinical outcomes, toxicity and prognostic factors on 142 patients (STEP Study)","volume":"30","author":"Comito","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0104","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.662205","article-title":"Risk adapted ablative radiotherapy after intensive chemotherapy for locally advanced pancreatic cancer","volume":"11","author":"Rossi","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0105","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1016\/j.clon.2020.06.019","article-title":"Hypofractionated stereotactic body radiation therapy with simultaneous integrated boost and simultaneous integrated protection in pancreatic ductal adenocarcinoma","volume":"33","author":"Simoni","year":"2021","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.07.002_bib0106","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.ijrobp.2025.03.049","article-title":"Feasibility of stereotactic body radiation therapy for pancreatic tumors abutting organs at risk using magnetic resonance guided adaptive radiation therapy","volume":"122","author":"D'Souza","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0107","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.radonc.2017.05.013","article-title":"An evaluation of motion mitigation techniques for pancreatic SBRT","volume":"124","author":"Campbell","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0108","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.3109\/0284186X.2014.905699","article-title":"Differences in respiratory-induced pancreatic tumor motion between 4D treatment planning CT and daily cone beam CT, measured using intratumoral fiducials","volume":"53","author":"Lens","year":"2014","journal-title":"Acta Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0109","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ijrobp.2014.10.058","article-title":"Modeling pancreatic tumor motion using 4-dimensional computed tomography and surrogate markers","volume":"91","author":"Huguet","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0110","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.ijrobp.2010.10.020","article-title":"Interfractional reproducibility in pancreatic position based on four-dimensional computed tomography","volume":"80","author":"Shiinoki","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0111","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.radonc.2014.03.002","article-title":"MRI-based tumor motion characterization and gating schemes for radiation therapy of pancreatic cancer","volume":"111","author":"Heerkens","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0112","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.ijrobp.2009.06.009","article-title":"Use of respiratory-correlated four-dimensional computed tomography to determine acceptable treatment margins for locally advanced pancreatic adenocarcinoma","volume":"76","author":"Goldstein","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0113","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/1748-717X-9-192","article-title":"The analysis of respiration-induced pancreatic tumor motion based on reference measurement","volume":"9","author":"Knybel","year":"2014","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0114","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160815","article-title":"Assessment with cone-beam computed tomography of intrafractional motion and interfractional position changes of resectable and borderline resectable pancreatic tumours with implanted fiducial marker","volume":"90","author":"Ohira","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2026.07.002_bib0115","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1259\/bjr\/17111751","article-title":"A preliminary probe into the movement of pancreatic lesions and factors that influence it","volume":"83","author":"Song","year":"2010","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2026.07.002_bib0116","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ijrobp.2013.04.012","article-title":"Management of respiration-induced motion with 4-dimensional computed tomography (4DCT) for pancreas irradiation","volume":"86","author":"Tai","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0117","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.radonc.2016.09.012","article-title":"Abdominal organ motion during inhalation and exhalation breath-holds: Pancreatic motion at different lung volumes compared","volume":"121","author":"Lens","year":"2016","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0118","article-title":"Current practices and perspectives on the integration of contrast agents in MRI-guided radiation therapy clinical practice: A worldwide survey","volume":"40","author":"Boldrini","year":"2023","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0119","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1441227","article-title":"Clinical experience with adaptive MRI-guided pancreatic SBRT and the use of abdominal compression to reduce treatment volume","volume":"14","author":"Ferris","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0120","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/MEG.0000000000000283","article-title":"Comparing outcomes of stereotactic body radiotherapy with intensity-modulated radiotherapy for patients with locally advanced unresectable pancreatic cancer","volume":"27","author":"Lin","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.prro.2026.07.002_bib0121","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COC.0b013e3181d270b4","article-title":"Stereotactic body radiotherapy in the treatment of advanced adenocarcinoma of the pancreas","volume":"34","author":"Rwigema","year":"2011","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0122","doi-asserted-by":"crossref","first-page":"e193","DOI":"10.1016\/j.prro.2014.08.019","article-title":"Comparison of implanted fiducial markers and self-expandable metallic stents for pancreatic image guided radiation therapy localization","volume":"5","author":"Pepin","year":"2015","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0123","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijrobp.2013.05.001","article-title":"Interfractional position variation of pancreatic tumors quantified using intratumoral fiducial markers and daily cone beam computed tomography","volume":"87","author":"van der Horst","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0124","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijrobp.2014.03.029","article-title":"Limited role for biliary stent as surrogate fiducial marker in pancreatic cancer: Stent and intratumoral fiducials compared","volume":"89","author":"van der Horst","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0125","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.prro.2015.11.007","article-title":"The dosimetric impact of image guided radiation therapy by intratumoral fiducial markers","volume":"6","author":"Yu","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0126","article-title":"Safety and efficacy of neoadjuvant SABR in pancreatic cancer: Effect of magnetic resonance imaging-guided respiratory-gated adaptive radiation therapy","volume":"9","author":"Song","year":"2024","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0127","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.842402","article-title":"Stereotactic MR-guided radiotherapy for pancreatic tumors: Dosimetric benefit of adaptation and first clinical results in a prospective registry study","volume":"12","author":"Michalet","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0128","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1040673","article-title":"Clinical outcomes after online adaptive MR-guided stereotactic body radiotherapy for pancreatic tumors on a 1.5 T MR-linac","volume":"13","author":"Eijkelenkamp","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0129","doi-asserted-by":"crossref","DOI":"10.1177\/10732748221150228","article-title":"Multi-institutional outcomes of patients aged 75 years and older with pancreatic ductal adenocarcinoma treated with 5-fraction ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART)","volume":"30","author":"Bryant","year":"2023","journal-title":"Cancer Control"},{"key":"10.1016\/j.prro.2026.07.002_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.phro.2022.10.003","article-title":"Stereotactic ablative radiation for pancreatic cancer on a 1.5 Telsa magnetic resonance-linac system","volume":"24","author":"Tringale","year":"2022","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0131","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1002\/cam4.2100","article-title":"Using adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer","volume":"8","author":"Rudra","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.prro.2026.07.002_bib0132","article-title":"Ablative five-fraction stereotactic body radiation therapy for inoperable pancreatic cancer using online MR-guided adaptation","volume":"6","author":"Hassanzadeh","year":"2021","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0133","article-title":"Causes of death among patients with initially inoperable pancreas cancer after induction chemotherapy and ablative 5-fraction stereotactic magnetic resonance image guided adaptive radiation therapy","volume":"8","author":"Chuong","year":"2023","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0134","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.prro.2020.09.005","article-title":"Ablative 5-fraction stereotactic magnetic resonance-guided radiation therapy with on-table adaptive replanning and elective nodal irradiation for inoperable pancreas cancer","volume":"11","author":"Chuong","year":"2021","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0135","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.tipsro.2020.06.001","article-title":"On-line adaptive MR guided radiotherapy for locally advanced pancreatic cancer: Clinical and dosimetric considerations","volume":"15","author":"Placidi","year":"2020","journal-title":"Tech Innov Patient Support Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0136","article-title":"Patient specific contouring region of interest for abdominal stereotactic adaptive radiotherapy","volume":"25","author":"Price","year":"2023","journal-title":"Phys Imaging Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0137","doi-asserted-by":"crossref","first-page":"216","DOI":"10.21037\/tcr-2025-1-2641","article-title":"Artificial intelligence applications in adaptive radiotherapy-a narrative review","volume":"15","author":"Chen","year":"2026","journal-title":"Transl Cancer Res"},{"key":"10.1016\/j.prro.2026.07.002_bib0138","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.ijrobp.2021.02.008","article-title":"Phase I trial of stereotactic body radiation therapy dose escalation in pancreatic cancer","volume":"110","author":"Courtney","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0139","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.3390\/jcm13092631","article-title":"Salvage ablative radiotherapy for isolated local recurrence of pancreatic adenocarcinoma following definitive surgery","volume":"13","author":"Dee","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.prro.2026.07.002_bib0140","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1748-717X-8-27","article-title":"Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection","volume":"8","author":"Habermehl","year":"2013","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0141","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1245\/s10434-017-6134-6","article-title":"Stereotactic body radiation therapy for isolated local recurrence after surgical resection of pancreatic ductal adenocarcinoma appears to be safe and effective","volume":"25","author":"Ryan","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0142","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.clon.2021.12.014","article-title":"Efficacy and safety of reirradiation with stereotactic body radiation therapy for locally recurrent pancreatic adenocarcinoma","volume":"34","author":"Reddy","year":"2022","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"10.1016\/j.prro.2026.07.002_bib0143","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.adro.2017.01.003","article-title":"Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma","volume":"2","author":"Koong","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0144","doi-asserted-by":"crossref","first-page":"52","DOI":"10.3389\/fonc.2018.00052","article-title":"Stereotactic body radiation therapy for locally progressive and recurrent pancreatic cancer after prior radiation","volume":"8","author":"Sutera","year":"2018","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0145","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.pan.2025.04.012","article-title":"Proposing oligo-recurrence criteria in pancreatic ductal adenocarcinoma: A stratified analysis of locoregional treatment benefits","volume":"25","author":"Yamane","year":"2025","journal-title":"Pancreatology"},{"key":"10.1016\/j.prro.2026.07.002_bib0146","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.ijrobp.2022.07.019","article-title":"Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes","volume":"114","author":"Elamir","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2026.07.002_bib0147","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.659987","article-title":"Clinical effects of stereotactic body radiation therapy targeting the primary tumor of liver-only oligometastatic pancreatic cancer","volume":"11","author":"Ji","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0148","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13014-024-02493-8","article-title":"Stereotactic body radiation therapy for the primary tumor and oligometastases versus the primary tumor alone in patients with metastatic pancreatic cancer","volume":"19","author":"Jiang","year":"2024","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0149","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/MPA.0000000000001822","article-title":"Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy in selected patients: Data from a multi-institutional retrospective study","volume":"50","author":"Lee","year":"2021","journal-title":"Pancreas"},{"key":"10.1016\/j.prro.2026.07.002_bib0150","doi-asserted-by":"crossref","first-page":"891","DOI":"10.21037\/apm-22-1417","article-title":"Palliative radiotherapy in pancreatic cancer: A retrospective study of 100 cases and regional patterns of practice","volume":"12","author":"Liu","year":"2023","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.prro.2026.07.002_bib0151","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.canrad.2018.02.004","article-title":"Clinical assessment of palliative radiotherapy for pancreatic cancer","volume":"22","author":"Tian","year":"2018","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.prro.2026.07.002_bib0152","doi-asserted-by":"crossref","DOI":"10.1016\/j.prro.2026.03.015","article-title":"Adaptive salvage stereotactic radiation for locoregional recurrence of pancreatic adenocarcinoma after surgery","author":"Lakomy","year":"2026","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0153","doi-asserted-by":"crossref","first-page":"e141","DOI":"10.1016\/S1470-2045(25)00714-4","article-title":"The OligoPanc project: An interdisciplinary expert consensus statement on oligometastatic pancreatic cancer","volume":"27","author":"Leonhardt","year":"2026","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0154","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2026.103968","article-title":"Celiac plexus radiosurgery for retroperitoneal pain in advanced cancer: A pre-specified secondary analysis of health-related quality of life in a phase II single-arm trial","volume":"95","author":"Barry","year":"2026","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.prro.2026.07.002_bib0155","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.prro.2025.07.004","article-title":"Celiac plexus radiosurgery for the management of pancreatic cancer pain: Key tips and considerations","volume":"16","author":"Glynn","year":"2026","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0156","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1245\/s10434-021-11258-6","article-title":"Disparities in access to oncologic care in pancreatic cancer: A systematic review","volume":"29","author":"Fonseca","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0157","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jamasurg.2015.4239","article-title":"Associations of socioeconomic variables with resection, stage, and survival in patients with early-stage pancreatic cancer","volume":"151","author":"Shapiro","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.prro.2026.07.002_bib0158","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s13014-023-02301-9","article-title":"Proton radiotherapy as a treatment strategy to increase survival in locally advanced pancreatic cancer in the body and tail: A retrospective study","volume":"18","author":"Ami","year":"2023","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2026.07.002_bib0159","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4354592","article-title":"Insurance status is related to receipt of therapy and survival in patients with early-stage pancreatic exocrine carcinoma","volume":"2017","author":"Boevers","year":"2017","journal-title":"J Cancer Epidemiol"},{"key":"10.1016\/j.prro.2026.07.002_bib0160","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.pan.2017.07.191","article-title":"Comparison of proton beam radiotherapy and hyper-fractionated accelerated chemoradiotherapy for locally advanced pancreatic cancer","volume":"17","author":"Maemura","year":"2017","journal-title":"Pancreatology"},{"key":"10.1016\/j.prro.2026.07.002_bib0161","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2605555","article-title":"Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer","volume":"395","author":"O'Reilly","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2026.07.002_bib0162","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.recesp.2021.06.016","article-title":"Declaraci\u00f3n PRISMA 2020: una gu\u00eda actualizada para la publicaci\u00f3n de revisiones sistem\u00e1ticas [The PRISMA 2020 statement: An updated guideline for reporting systematic reviews]","volume":"74","author":"Page","year":"2021","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.prro.2026.07.002_bib0163","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026002171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850026002171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T20:52:27Z","timestamp":1791060747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850026002171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":163,"alternative-id":["S1879850026002171"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2026.07.002","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2026.07.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Radiation Oncology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}